Product Theaters
Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. Sessions are non-CME and solely promotional in nature.
Information Coming Soon!
7-Year Follow-up of the POLARIX Study
Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 3
A BCMA-Directed Bispecific for the Treatment of Patients with R/R Multiple Myeloma After At Least 4 Prior Lines of Treatment
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 1
For in-person participants only
A Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 1
For in-person participants only
Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research
Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 4
For in-person participants only
Challenging the Status Quo in Thalassemia Management: Hear Patient Perspectives and Discover an Oral Treatment Option from Agios Pharmaceuticals
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 4
For in-person participants only
This session will include a perspective from a patient living with thalassemia
Changing the ET Conversation: A New Paradigm in ET Management
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 4
For in-person participants only
DARZALEX FASPRO + VRd: A Clinical Foundation from the CEPHEUS and PERSEUS Trials
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 291-292
For in-person participants only
Discover A New Oral-Based Regimen for First Relapse Myeloma
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 6
For in-person participants only
Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option
Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 3
For in-person participants only
First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 5
For in-person participants only
From Data to Decisions: Advancing Patient Care in 2L+ Follicular Lymphoma and R/R DLBCL
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 6
For in-person participants only
Gene Addition Therapy in Sickle Cell Disease: Connecting Clinical Outcomes With the Patient Journey
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 3
For in-person participants only
HYMPAVZI (marstacimab-hncq): Expanding Possibilities in Hemophilia Management and Case-Based Treatment Considerations
Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 2
For in-person participants only
Indolent Mastocytosis: Evolving Perspectives on Treatment and Patient Impact
Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 5
For in-person participants only
This session includes a patient perspective
Insights into a RRMM Patient and Care Partner Journey: Clinical Evidence for a BCMA-Directed Therapy
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 3
For in-person participants only
This session will include perspectives from a patient and caregiver
Learn About A Frontline Treatment Option in Peripheral T-Cell Lymphoma
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 288-290
For in-person participants only
Let’s Talk About Hemophilia Management Today
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 2
For in-person participants only
This session will include a patient perspective
OMISIRGE: Challenging Conventional Thinking About Time To Transplant And Patient Outcomes In Hematological Conditions With A Novel Cell Therapy Donor Source
Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 1
Ph+ CML-CP: A Nilotinib Treatment Option
Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 6
For in-person participants only
Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 3
For in-person participants only
This session will include perspectives from patients living with Hemophilia A and B
See How Jaypirca (pirtobrutinib) is Sparking More Possibilities
Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 2
For in-person participants only
The APP Perspective: Building Confidence With DARZALEX Faspro
Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 291-292
For in-person participants only
The Only BTKi Approved in 1L CLL/SLL and 1L MCL
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 5
For in-person participants only
Understanding Time off Treatment With an All-Oral, Fixed-Duration Regimen: Perspective of a Patient With Previously Untreated CLL
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 2
For in-person participants only
Understanding the Evolving Treatment Landscape of Relapsed/Refractory NPM1-mutated AML
Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 1
For in-person participants only
Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL
Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 2
For in-person participants only
WAYRILZ (rilzabrutinib) Real World Cases & Patient Experience
Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 4
For in-person participants only
This session will include a patient perspective